openPR Logo
Press release

Biologics Market Set for Rapid Growth, Future Trends by Top Key Players AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La

09-11-2019 08:06 AM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI Research)

Biologics Market

Biologics Market

Biological products include a wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for genetic disorders. New technologies, novel therapies are emerging for the manufacturing of new biologics which holds a prominent future for biologics market. Biologics are widely used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Biologics are also used in treatment of rare diseases in children like for treatment of Batten disease, cerliponase alfa was approved in 2017 for the first time by U.S. Food and Drug Administration (FDA).

The biologics market size is expected to boost owing to the increasing product pipeline from different companies like Merck and Co., Pfizer, Glaxosmithkline. Pfizer has a strong product pipeline for 2019 of biologics, biosimilars, vaccines and small molecules. 35 products are in phase 1, 28 are in phase 2 and 26 are in phase 3 and 11 products are in the process of registration. Total 100 products are in trial phase. Most recent approval by Pfizer is DAURISMO (glasdegib) in U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option.

To Know More About Biologics Market @ https://www.coherentmarketinsights.com/ongoing-insight/biologics-market-2663

Furthermore, the biologics market revenue is growing because of increasing number of Food and Drug Administration (FDA) approvals for new biologic medicines for treatment of rare diseases. For instance, in 2017 US FDA approved 46 biologics and in December 2017, GlaxoSmithKline's biologic Nucala was approved for the treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA).

North America holds dominant position in the global biologics market, owing to presence of major pharmaceutical and biopharmaceutical companies in the U.S. such as AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Novartis, Pfizer, and Sanofi with a great product portfolio in biologics. In 2018, 59 novel drugs and biologics were approved in by FDA's Center for Drug Evaluation and Research and were launched in the U.S.

Asia Pacific is anticipated to witness significant growth in biologics market size because of production and manufacturing of biosimilar products of biologics. A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. For instance, Indian biopharmaceutical company Biocon Ltd., launched two biosimilars CANMAb (trastuzumab) and Krabeva (bevacizumab) in India in year 2014 and 2017 respectively for treatment of several types of cancer.

Request Sample Copy of This Business Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2663

Global Biologics Market: Taxonomy

The global biologics market is segmented on the basis of product type, application, end user, and region.

By Product Type:

Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cell Therapy
Gene Therapy
By Application:

Oncology
Infectious Diseases
Immunology
Autoimmune Diseases
Others
Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Company Profiles:

AbbVie
Amgen
AstraZeneca
Biogen Idec
Bristol-Myers Squibb
Eli Lilly and Company
GlaxoSmithKline
Novartis
Pfizer
F. Hoffmann-La Roche Ltd
Sanofi

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2663

SOURCE: Coherent Market Insights

Mr. Raj Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biologics Market Set for Rapid Growth, Future Trends by Top Key Players AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La here

News-ID: 1831860 • Views: 154

More Releases from Coherent Market Insights (CMI Research)

Ureteral Stents Market Growth by 2026: Leading Key Players Like HydrUStent, LDA, …
Ureteral stents are minimally-invasive method of maintaining ureteral drainage to ensure renal function and treat pain caused due to ureteral obstruction. These stents are an integral part of the treatment of different urological conditions such as malignant obstruction, nephrolithiasis, ureteral stricture, ureteral injury, and healing. Increasing prevalence of urinary incontinence with age and rising geriatric population are major factors expected to drive the ureteral stents market growth during the forecast period.
Pharmacovigilance Market Recent Developments, Revenue by Top Key Players Accentu …
Europe is expected to hold a dominant position in the global pharmacovigilance market, over the forecast period. This is mainly due to introduction of new legislations in European Union in 2012, which ensures good vigilance practices for pharmaceutical companies and medicines regulators.. According to National Center for Biotechnology Information, in 2016, Europe accounted for high incidence of adverse drug reactions, around 5% of all hospital admissions were due to drug
Biosimilar Pipeline Analysis Market Global Industry by Top Players Pfizer Inc., …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Veterinary Vaccines Market Boosting the Growth 2026: Key Players Zoetis Inc. Mer …
Rapid increase in population of companion animals and livestock animals globally is one of the major factors expected to favor market growth for veterinary vaccines. Rise in awareness about the vaccination programs are further favoring growth of the global veterinary vaccines market. The market is estimated to witness considerable revenue traction over the forecast period, due to increasing incidence of food-borne zoonotic diseases worldwide. Also, rise in demand for white

All 5 Releases


More Releases for Biologics

Global Biologics Size and Segments
The Business Research Company’s global Biologics market report, covers the year-on-year growth of the global Biologics market historic and forecast growth. It also includes chapters on the Biologics market trends, Biologics geographical analysis, Biologics driver and restraints, and Biologics leading competitors’ revenues, profiles and market shares. Order The Global Biologics Market Report At: https://www.thebusinessresearchcompany.com/report/biologics-global-market-opportunities-and-strategies-to-2021 Global Biologics Market Segments The Biologics industry can be further categorized into -monoclonal antibodies (mAbs) market, therapeutic proteins market,
Plant-based Biologics
Increasing demand for biologics for various chronic diseases and rising investment in R&D for the production of biologics is expected to contribute significantly to the growth of plant-based biologics market. According to Biotechnology Innovation Organization (BIO) 2015, over 250 biologic therapies and vaccines have changed the lives of hundreds of millions of patients. Moreover, according to the same source, over 900 biologics are currently (2018) under the stage of development
Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Oral Biologics Market Opportunity Analysis, 2018-2026
Oral biologics represent a novel category of drugs, which is gaining traction in the last few decades. Biologic therapeutics has proven to be a highly effective treatment for various chronic ailments, such as diabetes, plaque psoriasis, arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The major concern regarding oral biologics is to protect the protein from degradation and digestion in the gastrointestinal tract. The first products were mostly insulin-related, novel
Spine Biologics Market Industry Analysis
Spine Biologics Market was worth USD 2.07 billion in 2016 and estimated to be growing at a CAGR of 4.4%, to reach USD 2.56 billion by 2021. Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries by stimulating bone growth formation through inflammatory stage, repair stage, and remodeling stage. Therefore, surge in the number of
Biologics Market | Key Opportunities And Forecast 2024
The Global Market For Biologics features a fragmented competitive landscape with stakeholders being some of the world’s most influential pharmaceutical companies and several domestic companies, which are vying for a share in the highly profitable market, observes Transparency Market Research (TMR) in a recent report. “A popular trend in the market is strategic mergers and acquisitions, with big companies wanting to expand their services and manufacturing units globally and enhancing